The following is from Reuters. Pfizer (PFE.N) on Tuesday [August 1] said it will launch a cost-cutting program if its Covid-19 vaccine and antiviral treatment keep underperforming expectations in the coming months due to plunging demand. Pfizer said it anticipates more clarity […]
Pfizer might need to cut costs, as demand for Covid products falls Read More »
The following is an excerpt from Fortune.com. For drugmaker Pfizer, a fortune amassed in the Covid pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions. The company has reaped nearly $100 billion from selling Covid-19
Pfizer uses Covid profits to try to invent new blockbuster drugs Read More »
The following is an excerpt from Time.com. Pfizer Inc. plans to stop enrollment in a study of its Covid-19 drug in patients who aren’t at high risk of severe disease after the pill didn’t help alleviate their symptoms, a major
Pfizer says: Paxlovid doesn’t work for healthier patients Read More »
The head of the U.S. Centers for Disease Control and Prevention, Dr. Rochelle Walensky has tested positive again for Covid-19. Walensky initially tested positive for Covid-19 on Oct. 21. The following statement was issued by the Centers for Disease Control and
(READ) CDC Director tests positive for Covid again Read More »
The following is an excerpt from WebMD. U.S. researchers are planning to study how often and why coronavirus levels come back for some Covid-19 patients who take Pfizer’s Paxlovid drug, according to Bloomberg News. “It is a priority,” Clifford Lane, MD,
Pfizer’s Paxlovid Covid-19 drug studied after reports of ‘relapses’ Read More »
